Heterocyclic compounds as monoacylglycerol lipase inhibitors
The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R 1 and R 2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
1. A compound, wherein the compound is:
or is a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 , wherein the compound is:
3. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a therapeutically inert carrier.
4. A pharmaceutical composition comprising the compound of claim 2 , and a therapeutically inert carrier.
5. A method of treating a neurodegenerative disease in a mammal in need thereof, comprising administering to the mammal an effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof.
6. The method of claim 5 , wherein the neurodegenerative disease is multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, traumatic brain injury, neurotoxicity, stroke, or epilepsy.
7. The method of claim 5 , wherein the neurodegenerative disease is multiple sclerosis, Alzheimer's disease, or Parkinson's disease.
8. The method of claim 5 , wherein the mammal is a human.
9. The method of claim 6 , wherein the mammal is a human.
10. The method of claim 7 , wherein the mammal is a human.